Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Disease Tremor: A Customized Approach
Latest Information Update: 16 Aug 2017
Price :
$35 *
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Parkinson's disease; Tremor
- Focus Therapeutic Use
- 05 Aug 2017 Results (n=30) published in the Mayo Clinic Proceedings
- 21 Apr 2016 Primary endpoint of Unified Parkinsons Disease Rating Scale (UPDRS) Tremor Scale has been met, according to results published in the 68th Annual Meeting of the American Academy of Neurology.
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology